Japan Tobacco (2914) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
5 Nov, 2025Executive summary
Six-month consolidated revenue rose 12.7% year-on-year to ¥1,734.5 billion, with AOP at constant FX up 24.7%, driven by organic growth and the Vector Group (VGR) acquisition.
Operating profit increased 10.9% to ¥479.9 billion, and profit attributable to owners rose 4.8% to ¥319.9 billion, despite impairment losses and higher amortization from acquisitions.
Comprehensive income decreased 40.9% year-on-year to ¥467.8 billion, mainly due to lower exchange differences on translation of foreign operations.
Early momentum for Ploom AURA and EVO in Japan, with device sales exceeding previous models by three times in the first three weeks and steady HTS share gains globally.
Announced transfer of the Pharmaceutical Business to Shionogi & Co., Ltd. and sale of subsidiary TORII PHARMACEUTICAL CO., LTD.
Financial highlights
Core revenue for Jan–Jun 2025: ¥1,724.5 billion (+14.2% at constant FX), reported revenue: ¥1,734.5 billion (+10.5%).
AOP: ¥565.1 billion (+24.7% at constant FX), reported AOP: ¥539.9 billion (+19.2%).
Operating profit: ¥479.9 billion (+10.9%), profit: ¥319.9 billion (+4.8%) year-on-year.
Tobacco business core revenue: ¥1,552.5 billion (+11.5%), AOP: ¥556.1 billion (+17.8%).
Processed food revenue: ¥76.7 billion (+2.9B), AOP: ¥2.6 billion (–1.8B); pharmaceutical revenue: ¥48.3 billion (+4.3B), AOP: ¥4.2 billion (+0.2B).
Outlook and guidance
Full-year 2025 core revenue forecast revised upward to ¥3,286.0 billion (+8.4% at constant FX), AOP to ¥862.0 billion (+14.6% at constant FX).
Operating profit forecast: ¥739.0 billion (+128.5%), profit: ¥494.0 billion (+175.6%).
Free cash flow forecast: –¥112.0 billion, reflecting Canadian litigation settlement and higher working capital.
Annual dividend per share forecast raised to ¥208.00, with interim dividend at ¥104.00; payout ratio set at 74.8–74.9%.
The group targets high single-digit annual average growth in adjusted operating profit at constant FX through 2027.
Latest events from Japan Tobacco
- Strong H1 2026 results and upgraded full-year outlook, led by tobacco and RRP growth.2914
Q2 2026 - Q1 2026 delivered strong revenue and profit growth, with robust outlook and high dividend forecast.2914
Q1 2026 - Record-high profit and revenue in FY2025, with robust outlook and continued RRP expansion.2914
Q4 2025 - Record-high profit and revenue, higher guidance, and increased dividend after business divestiture.2914
Q3 2025 - Strong tobacco pricing and RRP growth drove higher profit and raised full-year guidance.2914
Q2 2024 - Revenue up 11% and US market share expanded via Vector, but profit faces cost and litigation risks.2914
Q3 2024 - Q1 2025 saw robust profit growth, pharma divestment to Shionogi, and steady dividend guidance.2914
Q1 2025 - Record revenue and profit growth in FY2024, with high single-digit AOP growth targeted for 2025.2914
Q4 2024